Information Provided By:
Fly News Breaks for February 3, 2016
CPHD
Feb 3, 2016 | 07:47 EDT
Cowen lowered its price target on Cepheid to $35 from $40 citing lower than expected clinical reagents revenues and tough Q1 comps for its optics division. The firm expects revenue growth to accelerate in the second half of the year driven by new products, better execution and friendlier comps. Cowen reiterated its Outperform rating on Cepheid shares.
News For CPHD From the Last 2 Days
There are no results for your query CPHD